Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE
Over 36 months, pegcetacoplan continued to reduce GA growth with increasing efficacy over time and reduced formation of new scotomatous points. The safety profile of pegcetacoplan in the first 12 months of GALE was consistent with the prior 24-month OAKS and DERBY studies.
Authors
- Lawrence J. Singerman (ORCID: https://orcid.org/0000-0002-9048-8358)
- Allen Chiang (ORCID: https://orcid.org/0000-0002-0179-1006)
- Anat Loewenstein (ORCID: https://orcid.org/0000-0002-7706-1165)
- Frank Gerhard Holz (ORCID: https://orcid.org/0000-0001-8019-9272)
- Abhiram S. Vilupuru
- Jason Lin (ORCID: https://orcid.org/0000-0002-6277-8729)
- Jeffrey S. Heier (ORCID: https://orcid.org/0000-0003-4625-3145)
- Dilsher S. Dhoot (ORCID: https://orcid.org/0000-0002-1619-452X)
- Charles C. Wykoff (ORCID: https://orcid.org/0000-0001-7756-5091)
- David S. Boyer (ORCID: https://orcid.org/0000-0001-9219-1614)
- Jordi Monés (ORCID: https://orcid.org/0000-0003-3685-2160)
- Lejla Vajzovic (ORCID: https://orcid.org/0000-0002-4469-6834)
- Ashkan M. Abbey (ORCID: https://orcid.org/0000-0002-8719-6709)
- Caroline R. Baumal (ORCID: https://orcid.org/0000-0002-3651-8210)
- Chao Li (ORCID: https://orcid.org/0000-0001-5723-1414)
Institutions
- University of Bonn (DE)
- Tel Aviv University (IL)
- Duke University (US)
- University Hospital Bonn (DE)
- California Retina Consultants (US)
- Retina Consultants of Texas (US)
- Apellis Pharmaceuticals (United States) (US)
- Ophthalmic Consultants of Boston (US)
- Retina Vitreous Associates Medical Group (US)
- Barcelona Macula Foundation (ES)
- Texas Retina Associates (United States) (US)
- Case Western Reserve University (US)
- Wills Eye Hospital (US)
Publication Details
- Journal
- American Journal of Ophthalmology
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1016/j.ajo.2025.04.016
- Citations
- 7
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 11.95
Funders
- Apellis Pharmaceuticals